| Literature DB >> 29482749 |
Maria Cristina Marzola1, Sotirios Chondrogiannis2, Domenico Rubello2.
Abstract
Ovarian cancer is one of the most common gynecologic cancers and one of the leading causes of cancer death in women. It is often asymptomatic in early stages, and thus most patients are diagnosed when it is of advanced stage. For these reasons, the role of biomarkers and tomographic imaging is crucial. Fludeoxyglucose F 18 PET/CT is a useful imaging modality in different clinical settings of the disease, overcoming some limits of conventional imaging and influencing prognosis and therapeutic approaches. PET/MR imaging is an emerging modality, and its potential role remains to be explored.Entities:
Keywords: Biomarkers; FDG PET/CT; Ovarian cancer; Prognosis; Response to treatment; Staging
Mesh:
Substances:
Year: 2018 PMID: 29482749 DOI: 10.1016/j.cpet.2017.11.005
Source DB: PubMed Journal: PET Clin ISSN: 1556-8598